Drug Trial Radar · NCT02293265
Cross-sectional Study for Identification and Description of Severe Asthma Patients
Last checked: Nov 20, 2026Latest source record: Apr 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
767
Actual
Start
Dec 2014
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered. Approximately 790 subjects with severe asthma will be screened to achieve a total of at least 750 evaluable study subjects. The study will not include a run-in or follow-up period. This study will provide a more reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab. This study aims to estimate the potential overlap of patients eligible for treatment with mepolizumab and those eligible for treatment with omalizumab and/or reslizumab. Additionally, the current study will also ascertain and describe reslizumab eligibility with respect to both mepolizumab and omalizumab, in the severe asthma patient population.
Conditions
- Asthma
Interventions
Short Acting Beta Agonist (SABA)Drug
Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of severe asthma patients eligible for one or more biologic treatments for asthmaTime frame: Day 1
Locations
74 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Fresno, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Rolling Hills Estates, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Upland, California
GSK Investigational Site
Tallahassee, Florida
GSK Investigational Site
Owensboro, Kentucky
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Columbia, Maryland
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Plymouth, Minnesota
GSK Investigational Site
Corning, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Shelby, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Medford, Oregon
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Coffs Harbour, New South Wales, Australia
GSK Investigational Site
Sherwood Park, Alberta, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Burlington, Ontario, Canada
GSK Investigational Site
Grimsby, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
St-Charles-Borromée, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Trois-Rivières, Quebec, Canada
GSK Investigational Site
Bayonne, France
GSK Investigational Site
Dijon, France
GSK Investigational Site
Grenoble, France
GSK Investigational Site
Lille, France
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.